EUVIMEDEUVIMED entdecken
Multizentrische Studie

Characteristics, treatment and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort

Parveen Fathima iD, Edward Pan, Julie Marsh, Shivanthan Shanthikumar iD, Sheila Sivam, Adam Jaffe, Hiran Selvadurai, Ameneh Khatami, Geshani Jayasuriya, Richard Norman, Andrew Tai, Lucy Burr und 3 weitere

European Respiratory Journal · 2026

DOI: 10.1183/13993003.01349-2025 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Respiratory Journal, 2026. Verfasst von Parveen Fathima und 14 weiteren Autor:innen. Beteiligte Einrichtung: Health and Clinical Analytics, Sydney School of Public Health, The University of Sydney, Sydney, Australia parveen.fathima@sydney.edu.au. Hauptthemen laut MEDLINE: Cystic Fibrosis, Anti-Bacterial Agents, Lung, Pseudomonas Infections. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: MTPConnect Project Fund Program, BHP Blue Sky Award, Australian Medical Research Future Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary exacerbations pose a significant clinical burden on people with cystic fibrosis (pwCF). Whether management of exacerbations should change in the context of modulator therapy is unclear. We describe the characteristics, treatment and lung function outcomes of pulmonary exacerbations requiring intravenous antibiotic therapy (PERITs) in a contemporary Australian cohort of pwCF, in an era of rapidly broadening access to modulator therapy.

Methods

PwCF receiving care at 11 Australian specialist centres were prospectively enrolled between 14 October 2020 and 9 October 2024. Spirometry data and treatments received during a PERIT were collected systematically.

Results

A total of 982 pwCF were enrolled, with 593 PERITs recorded in 323 individuals. The median (interquartile range) age at PERIT start was 12 (7–17) years and the mean± sd baseline forced expiratory volume in 1 s (FEV 1 ) % predicted across PERITs was 80±21%. Approximately 62% (n=366) of PERITs occurred in people receiving modulator therapy. Intravenous tobramycin (63%) and piperacillin-tazobactam (43%) were the most frequently used antibiotics. Among participants with spirometry at baseline and at Day 7 (n=296) or Day 60 (n=383), 41% (n=120) and 44% (n=169) were below their baseline at Day 7 and Day 60 after commencing treatment, respectively; 8% were >10% below their baseline FEV 1 % predicted at both time-points. Recovery patterns were consistent regardless of baseline lung function, Pseudomonas aeruginosa colonisation or modulator use.

Conclusion

The pattern and magnitude of lung function impairment during PERITs is similar among those receiving and not receiving modulator therapy. This underscores the continued need for evidence to help clinicians balance treatment burden against the risk of irreversible loss of lung function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisAnti-Bacterial AgentsLungPseudomonas InfectionsHumansMaleFemaleChildAdolescentAustraliaForced Expiratory VolumeSpirometryProspective StudiesRespiratory Function TestsDisease ProgressionTreatment OutcomePseudomonas aeruginosa

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Health and Clinical Analytics, Sydney School of Public Health, The University of Sydney, Sydney, Australia parveen.fathima@sydney.edu.au.
  • Wesfarmers Centre of Vaccines and Infectious Diseases, The Kids Research Institute Australia, Perth, Australia.
  • Sydney Institute of Infectious Diseases (Sydney ID), Sydney, Australia.
  • Infection, Immunity and Global Health Theme, Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia.
  • Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
  • Respiratory and Sleep Medicine, Royal Children's Hospital, Melbourne, Australia.

ORCID-Profile: Parveen Fathima, Shivanthan Shanthikumar

Förderung

  • MTPConnect Project Fund Program
  • BHP Blue Sky Award
  • Australian Medical Research Future Fund

Zitieren

APA

Fathima, P., Pan, E., Marsh, J., Shanthikumar, S., Sivam, S., Jaffe, A., Selvadurai, H., Khatami, A., Jayasuriya, G., Norman, R., Tai, A., Burr, L., Mulrennan, S., Snelling, T., & Schultz, A. (2026). Characteristics, treatment and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort. European Respiratory Journal. https://doi.org/10.1183/13993003.01349-2025

Vancouver

Fathima P, Pan E, Marsh J, Shanthikumar S, Sivam S, Jaffe A, et al. Characteristics, treatment and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort. European Respiratory Journal. 2026. doi:10.1183/13993003.01349-2025

BibTeX
@article{Fathima2026,
  author = {Fathima, Parveen and Pan, Edward and Marsh, Julie and Shanthikumar, Shivanthan and Sivam, Sheila and Jaffe, Adam and Selvadurai, Hiran and Khatami, Ameneh and Jayasuriya, Geshani and Norman, Richard and Tai, Andrew and Burr, Lucy and Mulrennan, Siobhain and Snelling, Tom and Schultz, André},
  title = {Characteristics, treatment and lung function outcomes of pulmonary exacerbations in cystic fibrosis: insights from the BEAT-CF cohort},
  journal = {European Respiratory Journal},
  year = {2026},
  doi = {10.1183/13993003.01349-2025}
}
Kostenlos starten →